Scientific Opinion on the substantiation of a health claim related to Yestimun® and immune responses pursuant to Article 13(5) of Regulation (EC) No 1924/2006

Tabs

Article
Panel on Dietetic Products, Nutrition and Allergies
Acknowledgements

The Panel wishes to thank the members of the Working Group on Claims for the preparatory work on this opinion: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Marina Heinonen, Hannu Korhonen, Martinus Løvik, Ambroise Martin, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Inge Tetens, Hendrik van Loveren and Hans Verhagen.

EFSA Journal
EFSA Journal 2010; 8(5):1607 [11 pp.].
doi
10.2903/j.efsa.2010.1607
Panel members at the time of adoption
Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Hannu Korhonen, Pagona Lagiou, Martinus Løvik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Monika Neuhäuser-Berthold, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, Hendrik van Loveren and Hans Verhagen.
Contact
Type
Opinion of the Scientific Committee/Scientific Panel
On request from
Leiber GmbH
Question Number
EFSA-Q-2008-667
Adopted
30 April 2010
Published
26 May 2010
Affiliation
European Food Safety Authority (EFSA), Parma, Italy
Note
Abstract

Following an application from Leiber GmbH submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Germany, the Panel on Dietetic Products, Nutrition and Allergies was asked to deliver an opinion on the scientific substantiation of a health claim related to Yestimun® and the initiation of appropriate innate and adaptive immune responses. The scope of the application was proposed to fall under a health claim based on newly developed scientific evidence and including a request for the protection of proprietary data. The Panel considers that the food, Yestimun®, which consists of (1,3)-(1,6)-β-D-glucans from brewer’s yeast cell wall (100 % Saccharomyces cerevisiae), is sufficiently characterised. The target population is adults. The Panel considers that the initiation of appropriate innate and adaptive immune responses is a beneficial physiological effect. In weighing the evidence the Panel took into account that in the one human intervention study conducted with Yestimun® from which scientific conclusions could be drawn for the scientific substantiation of the claim, no effects of Yestimun® were observed on any outcome that could imply a beneficial effect on the initiation of appropriate innate and adaptive immune responses, and that the evidence provided in the animal and in vitro studies does not predict an effect of Yestimun® on the initiation of appropriate innate and adaptive immune responses in humans. The Panel concludes that a cause and effect relationship has not been established between the consumption of Yestimun® and the initiation of appropriate innate and adaptive immune responses.

Keywords
Yestimun®, beta-glucans, immune responses, health claims
Print on demand
Number of Pages
11